Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hedley

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 27, 2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancerD J Renouf, P A Tang, D Hedley, et al.
Cytometry. Part B, Clinical Cytometry|July 16, 2020
A multicenter study evaluation of the ClearLLab 10C panelsBenjamin D Hedley, Guoyan Cheng, Michael Keeney, et al.
British Journal of Cancer|July 30, 2014
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersT Golan, Z S Kanji, R Epelbaum, et al.
Cytometry. Part B, Clinical Cytometry|July 20, 2024
Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtainKatherine A Devitt, Wolfgang Kern, Malgorzata A Kajstura, et al.
Lancet (London, England)|May 17, 1980
The place of bone-marrow transplantation in acute myelogenous leukaemiaR L Powles, G Morgenstern, H M Clink, et al.
Molecular Diagnosis & Therapy|April 6, 2022
Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid MalignanciesPratibha Bhai, Cyrus C Hsia, Laila C Schenkel, et al.
Cytometry. Part B, Clinical Cytometry|September 15, 2025
Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel-recommendations and safeguards for clinical laboratoriesChristopher J Groves, Michael A Linden, Ahmad Al-Attar, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or <i>SF3B1</i> Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart ReviewShamim Mortuza, Benjamin Chin-Yee, Tyler E James, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimenE Warner, D Hedley, I Andrulis, et al.
International Journal of Laboratory Hematology|October 29, 2021
Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?Eri Kawata, Benjamin D Hedley, Benjamin Chin-Yee, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|May 27, 2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancerD J Renouf, P A Tang, D Hedley, et al.
Cytometry. Part B, Clinical Cytometry|July 16, 2020
A multicenter study evaluation of the ClearLLab 10C panelsBenjamin D Hedley, Guoyan Cheng, Michael Keeney, et al.
British Journal of Cancer|July 30, 2014
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersT Golan, Z S Kanji, R Epelbaum, et al.
Cytometry. Part B, Clinical Cytometry|July 20, 2024
Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtainKatherine A Devitt, Wolfgang Kern, Malgorzata A Kajstura, et al.
Lancet (London, England)|May 17, 1980
The place of bone-marrow transplantation in acute myelogenous leukaemiaR L Powles, G Morgenstern, H M Clink, et al.
Molecular Diagnosis & Therapy|April 6, 2022
Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid MalignanciesPratibha Bhai, Cyrus C Hsia, Laila C Schenkel, et al.
Cytometry. Part B, Clinical Cytometry|September 15, 2025
Ad hoc antibody modification of a validated flow cytometric immunophenotyping panel-recommendations and safeguards for clinical laboratoriesChristopher J Groves, Michael A Linden, Ahmad Al-Attar, et al.
Current Oncology (Toronto, Ont.)|April 26, 2024
Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or <i>SF3B1</i> Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart ReviewShamim Mortuza, Benjamin Chin-Yee, Tyler E James, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 1998
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimenE Warner, D Hedley, I Andrulis, et al.
International Journal of Laboratory Hematology|October 29, 2021
Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?Eri Kawata, Benjamin D Hedley, Benjamin Chin-Yee, et al.
Pageof 10